A Multicenter, Randomized, Double-Blind, Placebo-Controlled Staggered Dose-Escalating Phase IIb Study of the Safety and Efficacy of Istaroxime Over 24 Hours at Three Doses in Acute Decompensated Heart Failure Patients (The IGNITE Trial).

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Staggered Dose-Escalating Phase IIb Study of the Safety and Efficacy of Istaroxime Over 24 Hours at Three Doses in Acute Decompensated Heart Failure Patients (The IGNITE Trial).

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 08 May 2017

At a glance

  • Drugs Istaroxime (Primary)
  • Indications Decompensated heart failure
  • Focus Therapeutic Use
  • Acronyms IGNITE
  • Sponsors Debiopharm
  • Most Recent Events

    • 05 May 2017 This trial has been completed in France (End date:2009-09-04) as per European Clinical Trials Database.
    • 04 Jul 2012 Actual end date 3 Sep 2009 added as reported by EudraCT.
    • 04 Nov 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top